Vaniprevir/telaprevir/ribavirinAdis International Limited (now part of Wolters Kluwer Health)Adis International Limited (now part of Wolters Kluwer Health)2014DOI 10.1007/s40278-014-3577-4
Synthesis of Vaniprevir (MK-7009)Georg Thieme Verlag KGGeorg Thieme Verlag KG2011DOI 10.1055/s-0031-1289913
Phase Separation Macrocyclization in the Synthesis of VaniprevirGeorg Thieme Verlag KGGeorg Thieme Verlag KG2017DOI 10.1055/s-0036-1591212
Synthesis of Vaniprevir (MK-7009): Lactamization To Prepare a 22-Membered MacrocycleSong, Zhiguo J.American Chemical Society2011DOI 10.1021/jo2011494
Single‐Dose and Multiple‐Dose Pharmacokinetics of Vaniprevir in Healthy MenCaro, LWiley (Blackwell Publishing)2017DOI 10.1111/cts.12482
Synthesis of the HCV Protease Inhibitor Vaniprevir (MK-7009) Using Ring-Closing Metathesis StrategyKong, JongrockAmerican Chemical Society2012DOI 10.1021/jo3001595
Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease InhibitorMcCauley, John A.American Chemical Society2010DOI 10.1021/jm9015526
Liver-to-Plasma Vaniprevir (MK-7009) Concentration Ratios in HCV-Infected PatientsWright, D HamishInternational Medical Press2015DOI 10.3851/imp2958
Phase Separation Macrocyclization in a Complex Pharmaceutical Setting: Application toward the Synthesis of VaniprevirAmerican Chemical Society (ACS)American Chemical Society (ACS)DOI 10.1021/acs.joc.7b01308.s001
Phase Separation Macrocyclization in a Complex Pharmaceutical Setting: Application toward the Synthesis of VaniprevirGodin, ÉricAmerican Chemical Society2017DOI 10.1021/acs.joc.7b01308